Sovaldi In Medicaid: Contractor Molina Urges Government To Assume Up-Front Cost
Executive Summary
Medicaid managed care organization Molina says its 2014 payment rates are not adequate to cover the cost of Gilead Sciences’ hepatitis C drug Sovaldi and that the government should handle the upfront costs. WellPoint’s Medicaid plans have seen a 50% increase in the cost of treating hepatitis C patients.